Provided by Tiger Trade Technology Pte. Ltd.

Edgewise Therapeutics, Inc.

30.15
+0.07000.23%
Post-market: 30.150.00000.00%16:10 EST
Volume:566.13K
Turnover:17.15M
Market Cap:3.19B
PE:-19.19
High:31.20
Open:29.86
Low:29.72
Close:30.08
52wk High:31.29
52wk Low:10.60
Shares:105.87M
Float Shares:60.53M
Volume Ratio:0.67
T/O Rate:0.94%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5708
EPS(LYR):-1.4480
ROE:-30.02%
ROA:-20.66%
PB:5.71
PE(LYR):-20.82

Loading ...

Edgewise Therapeutics to Present at Guggenheim Emerging Outlook Biotech Summit

Reuters
·
Feb 05

Edgewise Therapeutics Grants Stock Options to New Employees Under Inducement Plan

Reuters
·
Feb 02

Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

THOMSON REUTERS
·
Feb 02

A Look At Edgewise Therapeutics (EWTX) Valuation After Detailed Late Stage Pipeline Milestone Update

Simply Wall St.
·
Jan 22

Edgewise Therapeutics provides priorities for 2026

TIPRANKS
·
Jan 13

BRIEF-Edgewise Therapeutics Provides Corporate Updates And Highlights Priorities For 2026

Reuters
·
Jan 13

Edgewise Therapeutics Inc - Prepare for Nda Submission for Sevasemten in Becker in H1 2027

THOMSON REUTERS
·
Jan 13

Edgewise Therapeutics Inc - to Initiate Edg-7500 Phase 3 Trial in Individuals With Obstructive and Nonobstructive HCM in Second Half of 2026

THOMSON REUTERS
·
Jan 13

Edgewise Therapeutics Inc - Anticipate Phase 2 Results for Edg-7500 in Hypertrophic Cardiomyopathy (HCM) in First Half of 2026

THOMSON REUTERS
·
Jan 13

Edgewise Therapeutics Provides Corporate Updates and Highlights Priorities for 2026

THOMSON REUTERS
·
Jan 13

A Look At Edgewise Therapeutics (EWTX) Valuation After Positive CIRRUS HCM Phase 2 Trial Update

Simply Wall St.
·
Jan 07

BRIEF-Edgewise Therapeutics Reports Inducement Grants As Permitted By The Nasdaq Listing Rules

Reuters
·
Jan 05

Edgewise Therapeutics Grants Stock Options to New Employees

Reuters
·
Jan 05

Edgewise Therapeutics Reports Inducement Grants as Permitted by the Nasdaq Listing Rules

THOMSON REUTERS
·
Jan 05

Top Midday Gainers

MT Newswires Live
·
Dec 25, 2025

Top Midday Stories: Apple's Cook Buys $3 Million in Nike Stock; OpenAI Explores Ads in ChatGPT; Sanofi-Dynavax $2.2 Billion Deal

MT Newswires Live
·
Dec 25, 2025

BUZZ-Edgewise Therapeutics rises on positive safety data from heart disease drug trial

Reuters
·
Dec 24, 2025

Update: Edgewise Therapeutics Shares Rise After Advancing Phase 2 Hypertrophic Cardiomyopathy Trial

MT Newswires Live
·
Dec 24, 2025

BRIEF-Edgewise Therapeutics Inc On Track To Deliver Full 12-Week Part D Readout In 2Q 2026 And Phase 3 Start In 4Q 2026

Reuters
·
Dec 24, 2025

Edgewise Therapeutics Reports Positive Interim Safety Results for EDG-7500 in Phase 2 CIRRUS-HCM Trial

Reuters
·
Dec 24, 2025